Genetic Technologies (Genetic Technologies) Total Payout Ratio : 0.00 (As of May. 13, 2024)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Genetic Technologies's current Total Payout Ratio is 0.00.

Genetic Technologies Total Payout Ratio Historical Data

The historical data trend for Genetic Technologies's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Total Payout Ratio Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Payout Ratio

Get a 7-Day Free Trial

0.55

3.46

2.25

0.61

Genetic Technologies Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Genetic Technologies's Total Payout Ratio

For the Diagnostics & Research subindustry, Genetic Technologies's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's Total Payout Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Total Payout Ratio falls into.

Genetic Technologies Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Genetic Technologies's Total Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	4.813	+	0)	/	-7.887
	=	0.61

Genetic Technologies's Total Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	0
	=	N/A

Genetic Technologies Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.